PPARD
Peroxisome proliferator-activated receptor delta
As of the edition of 20 October 2026, PPARD (peroxisome proliferator-activated receptor delta, UniProt Q03181) has 11 drugs tested at it and 13 companies on the list, 5 on route A and 2 on route B.
Sources: UniProt, ClinicalTrials.gov, ChEMBL, FDA Orange Book and Purple Book, Pharos.
The protein
- UniProt
- Q03181
- How well studied
- Chemical tools exist; no approved drug acts on it
- Where it sits in the cell
- Inside the cell
- Solved structures
- 56
- Disease areas
- Nutrition and metabolism; Digestive system; Hormones; Nervous system; Heart and blood vessels; Mental health; Pregnancy and women's health; Urinary and reproductive
- Registered trials of its drugs
- 97
Drugs at this target
| Status | Count |
|---|---|
| Marketed | 3 |
| Active | 3 |
| Went quiet | 3 |
| Stopped | 2 |
| Total | 11 |
| Drug | Status | Furthest phase | US protection |
|---|---|---|---|
| Elafibranor | Marketed | Phase 3 | Ends 2031 |
| Bezafibrate | Marketed | Phase 4 | none listed |
| Chiglitazar | Active | Phase 3 | none listed |
| Seladelpar | Marketed | Phase 3 | Ends 2031 |
| Mavodelpar | Stopped | Phase 3 | none listed |
| Lanifibranor | Active | Phase 3 | none listed |
| DB959 | Active | Phase 3 | none listed |
| Fonadelpar | Went quiet | Phase 3 | none listed |
| Indeglitazar | Stopped | Phase 2 | none listed |
| Sodelglitazar | Went quiet | Phase 2 | none listed |
| GW501516 | Went quiet | Phase 2 | none listed |
11 of 11 drugs, the most tested first.
Companies at this target
| Where the company stands | Companies |
|---|---|
| Route A | 5 |
| Route B | 2 |
| Engaged | 5 |
| Undetermined | 1 |
| Total on the list | 13 |
| Company | Route |
|---|---|
| Pfizer | Route A |
| Reneo Pharma | Route A |
| Ipsen | Route B |
The other 10 companies at PPARD
In the product13 companies in all; 10 are not named here, and no score is.
See the 13 companies at PPARD, ranked, with the facts behind eachRequest access. Nothing is shown until you do.